JP6642935B2 - 眼投与用の半フッ素化化合物 - Google Patents

眼投与用の半フッ素化化合物 Download PDF

Info

Publication number
JP6642935B2
JP6642935B2 JP2018515471A JP2018515471A JP6642935B2 JP 6642935 B2 JP6642935 B2 JP 6642935B2 JP 2018515471 A JP2018515471 A JP 2018515471A JP 2018515471 A JP2018515471 A JP 2018515471A JP 6642935 B2 JP6642935 B2 JP 6642935B2
Authority
JP
Japan
Prior art keywords
composition
compound
symptoms
composition according
semi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018515471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529693A (ja
JP2018529693A5 (enExample
Inventor
シェラー，ディーター
グリレンベルガー，ラルフ
レッシャー，フランク
フォス，ハルトムート
Original Assignee
ノバリック ゲーエムベーハー
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー, ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2018529693A publication Critical patent/JP2018529693A/ja
Publication of JP2018529693A5 publication Critical patent/JP2018529693A5/ja
Application granted granted Critical
Publication of JP6642935B2 publication Critical patent/JP6642935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C07C17/266—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018515471A 2015-09-30 2016-09-29 眼投与用の半フッ素化化合物 Active JP6642935B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15187760.2 2015-09-30
EP15187760 2015-09-30
EP15192429.7 2015-10-30
EP15192429 2015-10-30
PCT/EP2016/073262 WO2017055453A1 (en) 2015-09-30 2016-09-29 Semifluorinated compounds for ophthalmic administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019240070A Division JP7050741B2 (ja) 2015-09-30 2019-12-30 眼投与用の半フッ素化化合物

Publications (3)

Publication Number Publication Date
JP2018529693A JP2018529693A (ja) 2018-10-11
JP2018529693A5 JP2018529693A5 (enExample) 2019-12-19
JP6642935B2 true JP6642935B2 (ja) 2020-02-12

Family

ID=57068093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018515471A Active JP6642935B2 (ja) 2015-09-30 2016-09-29 眼投与用の半フッ素化化合物
JP2019240070A Active JP7050741B2 (ja) 2015-09-30 2019-12-30 眼投与用の半フッ素化化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019240070A Active JP7050741B2 (ja) 2015-09-30 2019-12-30 眼投与用の半フッ素化化合物

Country Status (14)

Country Link
US (2) US11154513B2 (enExample)
EP (3) EP3356313B1 (enExample)
JP (2) JP6642935B2 (enExample)
KR (2) KR102154415B1 (enExample)
CN (4) CN113662929A (enExample)
AU (3) AU2016329261B2 (enExample)
CA (1) CA2998269C (enExample)
DE (1) DE202016008739U1 (enExample)
DK (2) DK3722274T3 (enExample)
ES (2) ES2953837T3 (enExample)
MX (2) MX391587B (enExample)
PL (2) PL3356313T3 (enExample)
PT (1) PT3356313T (enExample)
WO (1) WO2017055453A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020073551A (ja) * 2015-09-30 2020-05-14 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP3192501B1 (en) 2011-05-25 2020-05-13 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
BR112015004997B1 (pt) 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
CN110403923B (zh) * 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
BR112019012791A2 (pt) * 2016-12-23 2019-12-03 Novaliq Gmbh composição oftálmica para o tratamento da doença do olho seco
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) * 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
KR102404412B1 (ko) 2018-09-27 2022-05-31 노바리크 게엠베하 국소 선스크린 제제
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
MX2022002667A (es) 2019-09-06 2022-04-07 Novaliq Gmbh Composicion oftalmica para el tratamiento de uveitis.
WO2025199627A1 (en) * 2024-03-26 2025-10-02 Apotex Inc Solid complexes comprising urea and semifluorinated alkanes

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
EP0983037B1 (en) 1998-02-09 2003-05-02 MacroChem Corporation Antifungal nail lacquer
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
IL141095A0 (en) 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
PT1666026E (pt) 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
CA2459483C (en) 2001-09-04 2009-06-23 Trommsdorff Gmbh & Co. Kg Arzneimittel Plaster for the treatment of dysfunctions and disorders of nail growth
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005018530A2 (en) 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
AU2004293027A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
ES2387619T3 (es) 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
EP1763336A1 (en) 2004-06-08 2007-03-21 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
KR20080043793A (ko) 2005-08-05 2008-05-19 바라트 쎄럼스 앤드 백신스 리미티드 방부 효능을 갖는 정맥 프로포폴 에멀젼 조성물
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) * 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
EP2070518A2 (en) 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
CA2659775A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008060359A2 (en) 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
MX2009005827A (es) 2006-12-07 2009-09-08 Sun Pharma Advanced Res Co Ltd Gotero con contador para administrar cantidades en microlitros de liquido en forma de gota.
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
ES2622582T3 (es) 2008-10-31 2017-07-06 University Of Mississippi Proceso para la preparación de ésteres de delta-9-THC-aminoácido
CA2743824A1 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
WO2010150378A1 (ja) 2009-06-25 2010-12-29 ライオン株式会社 眼科用組成物
RU2532027C2 (ru) 2009-07-24 2014-10-27 Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
DE102010022567A1 (de) * 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2819988C (en) 2011-01-04 2019-11-12 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
WO2012160180A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
EP3192501B1 (en) 2011-05-25 2020-05-13 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
BR112015004997B1 (pt) * 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
JP6039152B2 (ja) * 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
CA2943255C (en) 2014-03-31 2023-01-24 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
CN106572941B (zh) 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN110403923B (zh) * 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3698785A1 (en) 2016-09-28 2020-08-26 Novaliq GmbH Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
BR112019012791A2 (pt) 2016-12-23 2019-12-03 Novaliq Gmbh composição oftálmica para o tratamento da doença do olho seco

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020073551A (ja) * 2015-09-30 2020-05-14 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
JP7050741B2 (ja) 2015-09-30 2022-04-08 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物

Also Published As

Publication number Publication date
DE202016008739U1 (de) 2019-04-29
JP2018529693A (ja) 2018-10-11
EP3356313B1 (en) 2020-05-06
HK1257182A1 (en) 2019-10-18
AU2020205239A1 (en) 2020-07-30
JP2020073551A (ja) 2020-05-14
KR102154415B1 (ko) 2020-09-10
KR20200106097A (ko) 2020-09-10
WO2017055453A1 (en) 2017-04-06
MX2020001408A (es) 2022-04-13
AU2022200366B2 (en) 2023-11-09
US11154513B2 (en) 2021-10-26
CN110693825B (zh) 2022-03-08
ES2803248T3 (es) 2021-01-25
AU2016329261A1 (en) 2018-04-12
PL3722274T3 (pl) 2023-12-04
PT3356313T (pt) 2020-07-13
EP3722274A1 (en) 2020-10-14
PL3356313T3 (pl) 2020-11-16
CN108349855B (zh) 2021-07-20
AU2020205239B9 (en) 2021-10-28
DK3722274T3 (da) 2023-09-11
CN113662928A (zh) 2021-11-19
US20170087101A1 (en) 2017-03-30
AU2022200366A1 (en) 2022-02-17
AU2020205239B2 (en) 2021-10-21
EP3356313A1 (en) 2018-08-08
AU2016329261B2 (en) 2020-05-07
CN110693825A (zh) 2020-01-17
US20210315832A1 (en) 2021-10-14
ES2953837T3 (es) 2023-11-16
CN108349855A (zh) 2018-07-31
MX391587B (es) 2025-03-21
MX2018003781A (es) 2018-09-12
CA2998269A1 (en) 2017-04-06
EP4234523A1 (en) 2023-08-30
KR102584063B1 (ko) 2023-09-27
CN113662929A (zh) 2021-11-19
EP3722274B1 (en) 2023-06-07
DK3356313T3 (da) 2020-07-20
JP7050741B2 (ja) 2022-04-08
CA2998269C (en) 2021-03-23
KR20180059823A (ko) 2018-06-05

Similar Documents

Publication Publication Date Title
JP6642935B2 (ja) 眼投与用の半フッ素化化合物
JP6900442B2 (ja) 半フッ素化化合物およびその組成物
JP2018531233A6 (ja) 半フッ素化化合物およびその組成物
HK1257183A1 (en) Semifluorinated compounds and their compositions
HK40099432A (en) Semifluorinated compounds for ophthalmic administration
HK40039482A (en) 2-perfluorobutyl pentane for ophthalmic administration
HK40039482B (en) 2-perfluorobutyl pentane for ophthalmic administration
HK40006723B (en) Semifluorinated compounds and their compositions
HK40006723A (en) Semifluorinated compounds and their compositions
HK1257185B (en) Semifluorinated compounds and their compositions
HK1257007B (en) Semifluorinated compounds for ophthalmic administration
HK1257007A1 (en) Semifluorinated compounds for ophthalmic administration

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191104

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191104

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191230

R150 Certificate of patent or registration of utility model

Ref document number: 6642935

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250